Integra LifeSciences Holdings (NAS: IART) is expected to report Q2 earnings on July 26. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Integra LifeSciences Holdings' revenues will expand 6.2% and EPS will compress -1.4%.
The average estimate for revenue is $205.4 million. On the bottom line, the average EPS estimate is $0.69.
Last quarter, Integra LifeSciences Holdings logged revenue of $196.2 million. GAAP reported sales were 8.4% higher than the prior-year quarter's $181.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.71. GAAP EPS of $0.23 for Q1 were 39% lower than the prior-year quarter's $0.38 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 64.3%, 60 basis points worse than the prior-year quarter. Operating margin was 13.6%, 130 basis points worse than the prior-year quarter. Net margin was 3.4%, 290 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $829.8 million. The average EPS estimate is $3.02.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 159 members out of 169 rating the stock outperform, and 10 members rating it underperform. Among 57 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 55 give Integra LifeSciences Holdings a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Integra LifeSciences Holdings is outperform, with an average price target of $38.23.
The healthcare investing landscape is littered with also-rans and a few major winners. Is Integra LifeSciences Holdings performing well enough for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.
Add Integra LifeSciences Holdings to My Watchlist.
The article Are You Expecting This From Integra LifeSciences Holdings? originally appeared on Fool.com.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.